Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$159.69 USD

159.69
4,765,963

+0.16 (0.10%)

Updated Oct 8, 2024 04:00 PM ET

After-Market: $159.69 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (47 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Glaxo's (GSK) Begins Phase III HIV Two-Drug Regimen Study

Glaxo's (GSK) ViiV Healthcare commences phase III study on combo regimen of dolutegravir and lamivudine for maintenance of viral suppression in HIV-1 infection patients treated with TAF-based regimen.

    Theravance, J&J Ink Deal for Inflammatory Intestinal Drug

    Theravance (TBPH) signs a global collaboration agreement with Johnson & Johnson to jointly develop and commercialize TD-1473 for inflammatory intestinal diseases.

      Novartis' Cosentyx Label Expanded to Include Scalp Psoriasis

      Novartis' (NVS) psoriasis drug, Cosentyx is already approved for the treatment of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis.

        Merck (MRK) Beats on Q4 Earnings, Lags Sales, Guides for '18

        Merck (MRK) beats estimates for earnings but misses the same for sales in Q4. Sales of Keytruda remain strong in the quarter.

          Vertex (VRTX) Q4 Earnings Beat on Strong CF Products Sales

          Vertex Pharma (VRTX) fourth-quarter earnings increase from the year-ago period led by strong sales of CF drugs and lower operating expenses.

            Alkermes Submits NDA for Depression Candidate to the FDA

            Alkermes (ALKS) files a new drug application to the FDA for ALKS 5461's effective use in the adjunctive treatment of major depressive disorder (MDD).

              Amgen Gets CHMP Nod to Add ENDEAVOR Data on Kyprolis Label

              Amgen (AMGN) gains consent from the Committee for Medicinal Products for Human Use to add overall survival data from a phase III study on the label of its cancer drug, Kyprolis.

                Drug/Biotech Stocks Q4 Earnings Due on Jan 31: LLY & VRTX

                Two pharma/biotech giants are scheduled to report earnings on Jan 31. Let's take a look at how the companies are placed ahead of the upcoming releases.

                  Pfizer (PFE) Stock Falls Despite Q4 Earnings & Sales Beat

                  Pfizer (PFE) beats expectations for both earnings and revenues in Q4 and issues an upbeat guidance for 2018. However, shares decline in pre-market trading.

                    The Zacks Analyst Blog Highlights: Johnson & Johnson, Illinois Tool Works, Bank of New York Mellon, Ford and Capital One Financial

                    The Zacks Analyst Blog Highlights: Johnson & Johnson, Illinois Tool Works, Bank of New York Mellon, Ford and Capital One Financial

                      Mark Vickery headshot

                      Top Analyst Reports for Johnson & Johnson, Illinois Tool Works & BNY Mellon

                      Today's Research Daily features new research reports on 14 major stocks, including Johnson & Johnson (JNJ), Illinois Tool Works (ITW) and Bank of New York Mellon (BK).

                        AbbVie (ABBV) Q4 Earnings Beat, 2018 View Raised, Shares Up

                        AbbVie's (ABBV) Q4 earnings top estimates with revenues marginally beating the same. Sales of the company's lead marketed drug, Humira, also rise year over year.

                          Will J&J (JNJ) Witness Deceleration in 2018 Sales Growth?

                          J&J (JNJ) has a history of issuing a cautious outlook, especially at the beginning of the year. However, there are several tailwinds, which can coax it to improve the 2018 projection.

                            Zacks Earnings Trends Highlights: Citigroup, Johnson & Johnson, IBM and General Electric

                            Zacks Earnings Trends Highlights: Citigroup, Johnson & Johnson, IBM and General Electric

                              Will Pfizer (PFE) Surpass Estimates This Earnings Season?

                              While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive sales in Q4, genericization of key drugs and supply shortages in legacy Hospira products will hurt sales.

                                Pfizer's Rituxan Biosimilar Meets Endpoint in Phase III

                                Pfizer's (PFE) biosimilar version of Roche's blockbuster leukemia drug, Rituxan/Mabthera, meets primary endpoint in phase III comparative trial.

                                  Sweta Killa headshot

                                  Healthcare ETFs in Focus Post JNJ Q4 Results

                                  Investors should closely watch the movement of the JNJ following Q4 results and keep a close eye on ETFs having double-digit allocation to this diversified drug maker.

                                    Sheraz Mian headshot

                                    Four Things to Know About the Q4 Earnings Season

                                    There is clear momentum on the revenue side, both in terms of growth as well as more numerous revenue beats.

                                      Sheraz Mian headshot

                                      Four Things to Know About the Q4 Earnings Season

                                      There is clear momentum on the revenue side, both in terms of growth as well as more numerous revenue beats.

                                        J&J (JNJ) Q4 Earnings Top, Pharma Sales Continue to Improve

                                        J&J (JNJ) beat estimates for earnings while missing the same for sales in the fourth-quarter. It issued a mixed outlook for 2018.

                                          J&J (JNJ) Beats on Q4 Earnings, Misses Sales, Shares Up

                                          J&J (JNJ) beat estimates for earnings while missed the same for sales in the fourth-quarter. It issued a mixed outlook for 2018.

                                            Sheraz Mian headshot

                                            Earnings Momentum Driving Stocks

                                            The fact that estimates are going up is a big deal and a major change relative to what has been the norm over the last many years.

                                              Ryan McQueeney headshot

                                              3 Stocks Likely to Beat Earnings Estimates This Week

                                              Investors are always looking to find companies that are poised to post better-than-expected earnings results and experience strong post-earnings gains. Today, we are giving our readers a very special treat: a free look at three of the strongest stocks likely to beat earnings estimates this week.

                                                Sweta Killa headshot

                                                Healthcare ETFs to Watch As Q4 Earnings Unfold

                                                With earnings surprises well in the cards, the healthcare sector is expected to witness earnings growth of 3% in the fourth quarter, suggesting some upside for healthcare ETFs.

                                                  Wynn Resorts, Imax, Johnson & Johnson, Ford and Starbucks as Zacks Bull and Bear of the Day

                                                  Wynn Resorts, Imax, Johnson & Johnson, Ford and Starbucks as Zacks Bull and Bear of the Day